A retrospective study evaluating the safety of DOAC treatment in patients with advanced liver disease
Latest Information Update: 18 Aug 2021
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- 18 Aug 2021 New trial record
- 26 Jun 2021 Results presented at The International Liver Congress 2021